Adapted Physical Activity (APA) in a Breast Cancer Population.
Primary Purpose
Breast Neoplasms, Exercise, Exercise Therapy
Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Exercise
Sponsored by
About this trial
This is an interventional treatment trial for Breast Neoplasms
Eligibility Criteria
Inclusion Criteria:
- breast cancer patients in oncological follow-up
- post-menopausal age
- physically inactivity (light to moderate or vigorous leisure-time physical activity less than 10 minutes a day, US National Health Interview Survey)
- assuming or not hormone therapy
- after 3 months - 3 years from adjuvant post-surgical treatment (radiotherapy and/or chemotherapy)
Exclusion Criteria:
Permanent
- Patients older than 80 years
- Inability to carry on physical activity
- Metastatic neoplasia or unknown stage and/or histology
- Concomitant neoplasia
- Patients on corticosteroid treatment
- Known heart disease (heart failure NYHA II (New York Heart Association II) or superior, angina pectoris or positive exercise stress test, treatment-related cardiotoxicity)
- Currently on a weight loss plan or on moderate physical activity before the start of the project (no more than three sessions a week)
- Severe cachexia (loss of more than of 35% premorbid weight or weight loss more than 10% in the last 6 months).
- Morbidly obesity (BMI >40 kg/m2),
- Immunodepression (absolute neutrophils count < 500/mmc)
Temporary
- Uncontrolled pain or new onset bone pain until further diagnostic study
- Severe anemia (haemoglobin below 8 g/dL) or platelet count lower than <50000/μL
- Fever (temperature above 38ºC) or acute infections
- Severe nausea and vomiting within previous 24-36 h
- Uncontrolled blood pressure (systolic blood pressure > 160 mm Hg and/or diastolic blood pressure >99 mm Hg)
Sites / Locations
- University of Perugia
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Exercise
Control
Arm Description
Patients involved in the 6 months-physical training group.
Patients in control group carry on their usual follow-up programme.
Outcomes
Primary Outcome Measures
Change in physical activity levels
Self reported physical activity, using IPAQ-SF (International Physical Activity Questionnairev - Short Form) score
Change in BMI
Reduction of BMI expressed as body mass (kg) / height^2 (m^2)
Secondary Outcome Measures
Change in Post-Occlusive Reactive Hyperemia (PORH)
Improvement of Area of Hyperemia (AH) at Post-Occlusive Reactive Hyperemia (PORH) on Laser Doppler velocimetry (Periflux System 5000, Perimed), expressed as Perfusion Units (PU).
Carotid intima-media thickness (IMT)
Improvement of macrovascular structures, that will be explored by carotid intima-media thickness (IMT) (two-dimensional B-mode ultrasonography), measured in mm.
Arterial stiffness
Reduction of arterial stiffness, that will be evaluated by radial applanation tonometry (SphygmoCor) and general transfer function assessing PWV (measure in m/s).
Hemorheological profile
Improvement of Hemorheological profile, that will be studied with Serum, Plasma, and Blood Viscosity (Haake rotational viscometer), measured as mPas.
Serum adiponectin
Improvement of serum adiponectin, measured by ELISA-method (ng/ml). Blood samples will be collected in the morning between 7:00 and 9:00 am, after overnight fasting.
Serum IGF-1
Improvement of serum IGF-1, measured by ELISA-method (ng/ml). Blood samples will be collected in the morning between 7:00 and 9:00 am, after overnight fasting.
VFA (Visceral Fat Area)
Improvement of Ultrasound assesment of visceral fat area (VFA, by MyLab 50 Ultrasonography, Esaote), measured by Hirooka formula (cm^2)
HOMA-IR index
Homeostatic model assessment (HOMA) for insulin resistance (IR) is a method for assessing β-cell function and insuline resistance from basal (fasting) glucose and insulin or C-peptide concentrations. HOMA-IR can be calculated with a simple mathematical approximation as HOMA-IR = (FPI × FPG)/22.5, where FPI is fasting plasma insulin concentration (mU/l) and FPG is fasting plasma glucose (mmol/l), or as HOMA-IR = (FPI × FPG)/405 if fasting plasma glucose is expressed in mg/dl.
Values bethween 3 and 5 are considered expression of moderate insuline resistance; values upper 5 are considered expression of severe insuline resistance.
Improvement of insulin-sensitivity expressed as HOMA-IR index reduction.
Maximal aerobic capacity (VO2max)
Increase of maximal aerobic capacity after physical training, measured as ml/kg/min.
miRNA
Variation of serum miR-10b, 15a, 146, 155, 375 e let-7a,b,c concentrations.
Full Information
NCT ID
NCT03528473
First Posted
March 22, 2018
Last Updated
September 27, 2021
Sponsor
University Of Perugia
1. Study Identification
Unique Protocol Identification Number
NCT03528473
Brief Title
Adapted Physical Activity (APA) in a Breast Cancer Population.
Official Title
Adapted Physical Activity (APA), Insulin Resistance, Oxidative Stress and Microcirculatory Haemodynamics in Breast Cancer Patients.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Unknown status
Study Start Date
January 1, 2019 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Of Perugia
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this study is to investigate the effect of a 6-months program of Adapted Physical Activity (APA) on lifestyle, physical activity levels, insulin resistance and adipokines, oxidative stress, microcirculatory haemodynamics and serum levels of specific circulating miRNA in post-menopausal, physically inactive breast cancer patients in oncologic follow-up with or without hormone therapy that had completed adjuvant treatment (radiotherapy and/or chemotherapy) .
Furthermore, the study will determine the impact of APA on functional capabilities, on self-reported physical activity, quality of life and psychic health.
Detailed Description
This is a randomized controlled double-group assignment study with intermedial switch-over including post-menopausal, physically inactive breast cancer patients in oncological follow-up with or without hormone therapy, that had completed adjuvant post-surgical treatment (radiotherapy and/or chemotherapy) from at least 3 months and from not more than 3 years.
Patients in hormonal therapy and patient not in hormonal therapy will be assigned in two different groups, each one of 50 patients. In each groups, patients will be randomized divided in a control group (25 pt) and in a 6 months-physical training group (25 pt). After 6-months patient in control group will be switched in the physical training group.
The duration of the study is 2 year. Clinical evaluation of the patients will be made: at the enrollment, after 6, 12, and 24 months.
Physical activity will be adapted according to arm and shoulder morbidity, after fracture risk assessment. Exercise will be concentrated solely on leg muscles (pedalling on a cycle or bed ergometer) in individuals with limitations in the range of motion of the arms (eg, due to breast, axillary, or thoracic surgery). In patients experiencing ataxia, dizziness, or peripheral neuropathy, walking outdoors and mostly cycle-ergometry training will be preferred to other activities that also involve large muscle groups but require additional balance and coordination (eg, treadmill walking, outdoor cycling).
Exercises will be performed at the Unipolar Spinal Unit of "S. Maria della Misericordia" Hospital, Perugia.
The aim of the study is to confirm the positive effect of APA on metabolic stress, body mass composition, functional capacity, serum levels of specific circulating miRNA and quality of life in breast cancer patients in oncological follow-up.
Currently, only few data are available about the relationship between physical activity and microcirculatory hemodynamics that, together with oxidative stress, could be involved in genesis and progression of breast cancer.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Neoplasms, Exercise, Exercise Therapy, Insulin Resistance, Oxidative Stress, Microcirculation, Quality of Life, Atherosclerosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This is a randomized, controlled, double-group assignment, open label study with intermediate crossover
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Exercise
Arm Type
Experimental
Arm Description
Patients involved in the 6 months-physical training group.
Arm Title
Control
Arm Type
No Intervention
Arm Description
Patients in control group carry on their usual follow-up programme.
Intervention Type
Other
Intervention Name(s)
Exercise
Intervention Description
The exercise intervention consists of 60 minutes sessions, divided into 40 minutes of aerobic exercise and 20 minutes of circuit training for muscular strength and flexibility exercises.
Aerobic exercise is performed using treadmill, exercise bikes, syncro and arm-ergometers, gradually increasing the exercise intensity, after a 10 minutes period of warming-up, to 60-80 % of Maximum Heart Rate.
Resistance training consists of resistance exercises for large muscle groups, performed with body weight-exercises and isotonic machines.
Primary Outcome Measure Information:
Title
Change in physical activity levels
Description
Self reported physical activity, using IPAQ-SF (International Physical Activity Questionnairev - Short Form) score
Time Frame
Evaluation baseline and after 6, 12 and 24 months from enrollment.
Title
Change in BMI
Description
Reduction of BMI expressed as body mass (kg) / height^2 (m^2)
Time Frame
Evaluation baseline and after 6, 12 and 24 months from enrollment.
Secondary Outcome Measure Information:
Title
Change in Post-Occlusive Reactive Hyperemia (PORH)
Description
Improvement of Area of Hyperemia (AH) at Post-Occlusive Reactive Hyperemia (PORH) on Laser Doppler velocimetry (Periflux System 5000, Perimed), expressed as Perfusion Units (PU).
Time Frame
Evaluation baseline and after 6, 12 and 24 months from enrollment.
Title
Carotid intima-media thickness (IMT)
Description
Improvement of macrovascular structures, that will be explored by carotid intima-media thickness (IMT) (two-dimensional B-mode ultrasonography), measured in mm.
Time Frame
Evaluation baseline and after 6, 12 and 24 months from enrollment.
Title
Arterial stiffness
Description
Reduction of arterial stiffness, that will be evaluated by radial applanation tonometry (SphygmoCor) and general transfer function assessing PWV (measure in m/s).
Time Frame
Evaluation baseline and after 6, 12 and 24 months from enrollment.
Title
Hemorheological profile
Description
Improvement of Hemorheological profile, that will be studied with Serum, Plasma, and Blood Viscosity (Haake rotational viscometer), measured as mPas.
Time Frame
Evaluation baseline and after 6, 12 and 24 months from enrollment.
Title
Serum adiponectin
Description
Improvement of serum adiponectin, measured by ELISA-method (ng/ml). Blood samples will be collected in the morning between 7:00 and 9:00 am, after overnight fasting.
Time Frame
Evaluation baseline and after 6, 12 and 24 months from enrollment.
Title
Serum IGF-1
Description
Improvement of serum IGF-1, measured by ELISA-method (ng/ml). Blood samples will be collected in the morning between 7:00 and 9:00 am, after overnight fasting.
Time Frame
Evaluation baseline and after 6, 12 and 24 months from enrollment.
Title
VFA (Visceral Fat Area)
Description
Improvement of Ultrasound assesment of visceral fat area (VFA, by MyLab 50 Ultrasonography, Esaote), measured by Hirooka formula (cm^2)
Time Frame
Evaluation baseline and after 6, 12 and 24 months from enrollment.
Title
HOMA-IR index
Description
Homeostatic model assessment (HOMA) for insulin resistance (IR) is a method for assessing β-cell function and insuline resistance from basal (fasting) glucose and insulin or C-peptide concentrations. HOMA-IR can be calculated with a simple mathematical approximation as HOMA-IR = (FPI × FPG)/22.5, where FPI is fasting plasma insulin concentration (mU/l) and FPG is fasting plasma glucose (mmol/l), or as HOMA-IR = (FPI × FPG)/405 if fasting plasma glucose is expressed in mg/dl.
Values bethween 3 and 5 are considered expression of moderate insuline resistance; values upper 5 are considered expression of severe insuline resistance.
Improvement of insulin-sensitivity expressed as HOMA-IR index reduction.
Time Frame
Evaluation baseline and after 6, 12 and 24 months from enrollment.
Title
Maximal aerobic capacity (VO2max)
Description
Increase of maximal aerobic capacity after physical training, measured as ml/kg/min.
Time Frame
Evaluation baseline and after 6, 12 and 24 months from enrollment.
Title
miRNA
Description
Variation of serum miR-10b, 15a, 146, 155, 375 e let-7a,b,c concentrations.
Time Frame
Evaluation baseline and after 6, 12 and 24 months from enrollment.
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
breast cancer patients in oncological follow-up
post-menopausal age
physically inactivity (light to moderate or vigorous leisure-time physical activity less than 10 minutes a day, US National Health Interview Survey)
assuming or not hormone therapy
after 3 months - 3 years from adjuvant post-surgical treatment (radiotherapy and/or chemotherapy)
Exclusion Criteria:
Permanent
Patients older than 80 years
Inability to carry on physical activity
Metastatic neoplasia or unknown stage and/or histology
Concomitant neoplasia
Patients on corticosteroid treatment
Known heart disease (heart failure NYHA II (New York Heart Association II) or superior, angina pectoris or positive exercise stress test, treatment-related cardiotoxicity)
Currently on a weight loss plan or on moderate physical activity before the start of the project (no more than three sessions a week)
Severe cachexia (loss of more than of 35% premorbid weight or weight loss more than 10% in the last 6 months).
Morbidly obesity (BMI >40 kg/m2),
Immunodepression (absolute neutrophils count < 500/mmc)
Temporary
Uncontrolled pain or new onset bone pain until further diagnostic study
Severe anemia (haemoglobin below 8 g/dL) or platelet count lower than <50000/μL
Fever (temperature above 38ºC) or acute infections
Severe nausea and vomiting within previous 24-36 h
Uncontrolled blood pressure (systolic blood pressure > 160 mm Hg and/or diastolic blood pressure >99 mm Hg)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Leonella Pasqualini, MD
Organizational Affiliation
University Of Perugia
Official's Role
Study Director
Facility Information:
Facility Name
University of Perugia
City
Perugia
ZIP/Postal Code
06132
Country
Italy
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
28606800
Citation
Adraskela K, Veisaki E, Koutsilieris M, Philippou A. Physical Exercise Positively Influences Breast Cancer Evolution. Clin Breast Cancer. 2017 Oct;17(6):408-417. doi: 10.1016/j.clbc.2017.05.003. Epub 2017 May 19.
Results Reference
background
PubMed Identifier
24292096
Citation
Foucaut AM, Berthouze-Aranda SE, Touillaud M, Kempf-Lepine AS, Baudinet C, Meyrand R, Carretier J, Bachmann P, Fervers B. Reduction of health risk factors through an adapted physical activity program in patients with breast cancer. Support Care Cancer. 2014 Apr;22(4):1097-104. doi: 10.1007/s00520-013-2065-3. Epub 2013 Dec 3.
Results Reference
background
PubMed Identifier
22144472
Citation
Franses JW, Edelman ER. The evolution of endothelial regulatory paradigms in cancer biology and vascular repair. Cancer Res. 2011 Dec 15;71(24):7339-44. doi: 10.1158/0008-5472.CAN-11-1718. Epub 2011 Dec 5.
Results Reference
background
PubMed Identifier
23929213
Citation
Ye J, Jia J, Dong S, Zhang C, Yu S, Li L, Mao C, Wang D, Chen J, Yuan G. Circulating adiponectin levels and the risk of breast cancer: a meta-analysis. Eur J Cancer Prev. 2014 May;23(3):158-65. doi: 10.1097/CEJ.0b013e328364f293.
Results Reference
background
PubMed Identifier
23906304
Citation
Tesarova P, Kalousova M, Zima T, Suchanek M, Malikova I, Kvasnicka J, Duskova D, Tesar V, Vachek J, Krupickova-Kasalova Z, Malik J. Endotelial activation and flow-mediated vasodilation in young patients with breast cancer. Neoplasma. 2013;60(6):690-7. doi: 10.4149/neo_2013_088.
Results Reference
background
Learn more about this trial
Adapted Physical Activity (APA) in a Breast Cancer Population.
We'll reach out to this number within 24 hrs